NEW YORK/LONDON (Reuters) - Unlocking the potential of Genzyme's experimental multiple sclerosis drug Campath could be key to prying a higher price for the U.S. biotech from Sanofi-Aventis . Campath ...

Less than two months after Genzyme’s newest drug to treat multiple sclerosis was approved in Europe, U.S. regulators said in a report today that its health risk may outweigh the benefits, and ...

(AP) The U.S. Food and Drug Administration has notified drug maker Genzyme that its treatment for multiple sclerosis is not ready for approval for the American market. The French pharmaceutical ...

How do you whittle 35 years of headlining business news down to a couple thousand words and a few pages? You don't. But here, we take our best shot to highlight the companies, individuals, and moments ...